Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Valrox, Potential Hemophilia A Gene Therapy, May Cost Up to $3 Million, BioMarin Says

BioMarin is considering pricing its hemophilia A gene therapy Valrox (valoctocogene roxaparvovec), should it be approved, at $2 million to $3 million. That range would make Valrox the world’s most expensive one-time therapy. But, the company argues, this first gene therapy for any form of...